Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Gains from Sales and Divestitures (2022 - 2025)

Q32 Bio (QTTB) has 3 years of Gains from Sales and Divestitures data on record, last reported at $106737.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $106737.0; the TTM value through Dec 2025 reached $106737.0, changed N/A, while the annual FY2025 figure was $106737.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $106737.0 in Q4 2025 per QTTB's latest filing, roughly flat from $106737.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $373519.0 in Q4 2023 and bottomed at $87140.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 3 years is $164192.0, with a median of $106813.5 recorded in 2022.
  • The widest YoY moves for Gains from Sales and Divestitures: up 249.44% in 2023, down 123.23% in 2023.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $106890.0 in 2022, then soared by 249.44% to $373519.0 in 2023, then crashed by 71.42% to $106737.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $106737.0 in Q4 2025, $106737.0 in Q3 2025, and $373519.0 in Q4 2023.